Company News
Novartis Experimental Prostate Drug 85% PSA Reduction
Novartis reported early data from a 101‑patient trial of its actinium‑based experimental prostate cancer drug showing significant anti‑tumour activity.
52.5% of patients previously treated with Pluvic